[Acute Clostridium difficile gastroenteritis at the department of infectious diseases]. / Clostridium difficile okozta akut gastroenteritis fertozoosztályon.

INTRODUCTION: Clostridium difficile infection is known as the primary cause of nosocomial gastroenteritis, which accounts for approximately 20-25% of all diarrhea. Infection can lead to a potentially fatal disease and the incidence of that is increasing worldwide. AIM: The aim of the authors was to examine retrospectively the growing importance of Clostridium difficile infections at the Infectology Department of the University of Szeged, Hungary. METHODS: Patients with acute gastroenteritis admitted to the Department from 2005 to 2006 and from 2008 to 2011 were studied. RESULTS: In 2005 and 2006, Salmonella infections occurred most frequently, followed by Campylobacter species and toxin-producing Clostridium difficile infections. From 2008 the authors witnessed a continuous increase in the incidence of Clostridium difficile infections. As a result, toxin positive Clostridium difficile became the leading pathogenic agent among patients with acute gastroenteritis by the year of 2009. Besides demonstrating the increasing incidence and severity of Clostridium difficile infection, prognostic factors such as co-morbidities and laboratory parameters of inflammation were also identified. CONCLUSION: The results confirm the increasing importance of Clostridium difficile infection among patients with acute gastroenteritis.

Cardiac Repair and Regeneration: The Value of Cell Therapies.

Ischaemic heart disease is the predominant contributor to cardiovascular morbidity and mortality; one million myocardial Infarctions occur per year in the USA, while more than five million patients suffer from chronic heart failure. Recently, heart failure has been singled out as an epidemic and is a staggering clinical and public health problem associated with significant mortality, morbidity and healthcare expenditures, particularly among those aged ≥65 years. Death rates have improved dramatically over the last four decades, but new approaches are nevertheless urgently needed for those patients who go on to develop ventricular dysfunction and chronic heart failure. Over the past decade, stem cell transplantation has emerged as a promising therapeutic strategy for acute or chronic ischaemic cardiomyopathy. Multiple candidate cell types have been used in preclinical animal models and in humans to repair or regenerate the injured heart, either directly or indirectly (through paracrine effects), including: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), neonatal cardiomyocytes, skeletal myoblasts (SKMs), endothelial progenitor cells, bone marrow mononuclear cells (BMMNCs), mesenchymal stem cells (MSCs) and, most recently, cardiac stem cells (CSCs). Although no consensus has emerged yet, the ideal cell type for the treatment of heart disease should: (a) improve heart function; (b) create healthy and functional cardiac muscle and vasculature, integrated into the host tissue; (c) be amenable to delivery by minimally invasive clinical methods; (d) be available 'off the shelf' as a standardised reagent; (e) be tolerated by the immune system; (f) be safe oncologically, i.e. not create tumours; and (g) circumvent societal ethical concerns. At present, it is not clear whether such a 'perfect' stem cell exists; what is apparent, however, is that some cell types are more promising than others. In this brief review, we provide ongoing data on agreement and controversy arising from clinical trials and touch upon the future directions of cell therapy for heart disease.